Background: Although Coronavirus Disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develops severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics.
Methods: A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion.
Results: Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available.
Conclusions: Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare children who develop severe or critical disease, this guidance offer an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated.
Keywords: COVID-19; SARS-CoV-2; antiviral; guidance; pediatric.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: firstname.lastname@example.org.
Delayed Initiation of Remdesivir in a COVID-19-Positive Patient.Pharmacotherapy. 2020 Apr 13:10.1002/phar.2403. doi: 10.1002/phar.2403. Online ahead of print. Pharmacotherapy. 2020. PMID: 32281114 Free PMC article.
Old and re-purposed drugs for the treatment of COVID-19.Expert Rev Anti Infect Ther. 2020 Jun 1:1-5. doi: 10.1080/14787210.2020.1771181. Online ahead of print. Expert Rev Anti Infect Ther. 2020. PMID: 32419524
Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19.Pharmacotherapy. 2020 May 23. doi: 10.1002/phar.2429. Online ahead of print. Pharmacotherapy. 2020. PMID: 32446287 Review.
An overview of coronaviruses including the SARS-2 coronavirus - Molecular biology, epidemiology and clinical implications.Curr Med Res Pract. 2020 Apr 9. doi: 10.1016/j.cmrp.2020.04.001. Online ahead of print. Curr Med Res Pract. 2020. PMID: 32363221 Free PMC article. Review.
Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective.Endocr Metab Immune Disord Drug Targets. 2020 Apr 27. doi: 10.2174/1871530320666200427112902. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 32338224
Cited by 1 article
Facing the COVID-19 outbreak in children with cancer.Drugs Context. 2020 May 12;9:2020-4-12. doi: 10.7573/dic.2020-4-12. eCollection 2020. Drugs Context. 2020. PMID: 32435268 Free PMC article.